• Intellipharmaceutics International Inc., of Toronto, said it reached an agreement with London-based AstraZeneca plc to settle all outstanding patent litigation concerning its abbreviated new drug application to commercialize a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) tablets. The settlement provides, in part, that the company is permitted to launch generic versions on Nov. 1, 2016, or earlier under certain circumstances, subject to FDA approval.
To read more on related topics, click on one of the words below.